Equities

AnGes Inc

AnGes Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)46.00
  • Today's Change1.00 / 2.22%
  • Shares traded652.20k
  • 1 Year change-63.49%
  • Beta1.9586
Data delayed at least 20 minutes, as of Jun 11 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

  • Revenue in JPY (TTM)249.94m
  • Net income in JPY-6.35bn
  • Incorporated1999
  • Employees145.00
  • Location
    AnGes IncSaito Bio-Incubator, 7-7-15, Saito-AsagiIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 357302641
  • Websitehttps://www.anges.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TMS Co Ltd0.00-960.04m8.18bn14.00--2.37-----25.89-25.890.0085.770.00----0.00-26.14---26.78-------------2,219.420.00-------11.51------
Kohjin Bio Co Ltd4.77bn384.98m8.63bn157.0021.992.5321.171.8176.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
Noile-Immune Biotech Inc311.30m-975.80m8.66bn28.00--1.62--27.82-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.81bn292.0080.590.730290.161.143.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
CanBas Co Ltd (Parent)0.00-1.09bn9.05bn12.00--3.02-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc673.53m-641.32m9.11bn10.00--6.66--13.52-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
K Pharma Inc500.00m-221.98m9.45bn15.00--3.29--18.89-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
Linical Co Ltd12.31bn338.27m9.85bn759.0026.571.0911.500.8014.9814.98544.93364.600.6837--3.59--1.884.013.156.3330.7030.992.755.48----0.260350.10-1.671.70-66.32-9.86-10.184.56
AnGes Inc249.94m-6.35bn10.53bn145.00--0.3696--42.14-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED19.43bn299.18m11.24bn387.0037.500.51424.810.578661.1761.173,971.904,460.940.49571.663.80--0.76593.150.9973.9427.1725.241.555.850.6907115.660.320743.884.441.19-56.72-20.82-3.2910.76
Stella Pharma Corp269.49m-763.75m11.28bn46.00--4.69--41.87-24.63-24.638.7076.120.06610.05083.98---18.74-22.50-21.00-24.8380.63---283.40-488.655.52-379.390.2819--17.65--1.94---5.87--
Medinet Co Ltd711.82m-1.40bn11.29bn98.00--2.02--15.85-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
Nano Mrna Co Ltd135.51m-780.00m12.11bn17.00--3.54--89.35-11.10-11.101.9348.610.02559.029.66---14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
ReproCell Inc2.43bn-31.42m12.35bn92.00--1.48162.765.09-0.3465-0.346528.3493.450.27885.415.60---0.3609-7.35-0.3932-8.0046.1939.83-1.29-27.1610.54-------17.8317.3989.71--13.27--
3-D Matrix Ltd3.74bn-1.06bn12.62bn108.00--19.63--3.37-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
Data as of Jun 11 2024. Currency figures normalised to AnGes Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.61%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 09 May 20241.08m0.49%
SSgA Funds Management, Inc.as of 09 May 2024109.70k0.05%
Dimensional Fund Advisors LPas of 30 Apr 202480.10k0.04%
SPARX Asset Management Co., Ltd.as of 10 Mar 202340.30k0.02%
Dimensional Fund Advisors Ltd.as of 09 May 202425.56k0.01%
BlackRock Investment Management (UK) Ltd.as of 31 Jul 20230.000.00%
More ▼
Data from 28 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.